舒洛地特研究进展及临床应用

摘要/Abstract

摘要： 舒洛地特是一种新型天然糖胺聚糖, 含有的两个主成分作用原理不同而协同增效, 具有抗凝、溶栓、抗心血管疾病、降血脂、保护肾脏等作用, 近年来在治疗心血管疾病、周围动脉疾病、静脉炎后综合征、糖尿病并发症, 尤其糖尿病肾病等方面的临床应用引起了人们的关注, 本文就其化学成分、药代动力学、生物活性、质量控制、作用机制与药理、临床研究与应用, 以及近年来的研究进展进行综述。与同类药肝素比, 舒洛地特由于可口服, 生物利用率高, 副作用小, 并具有肝素所没有的分解脂肪作用, 可以认为应用将更广泛。目前国内只有进口产品, 国内厂家正处于研发阶段,相信不久将来会有国产舒洛地特。

关键词: 舒洛地特, 低分子肝素, 硫酸皮肤素, 抗血栓, 心血管疾病, 糖尿病肾病

Abstract: Sulodexide is a new type of natural glycosaminogly cans, contains two main components to different synergistic action principle, with anticoagulation, thrombolysis, ant i-cardiovascular disease, reducing blood lipid, protecting the kidneys and other role, In recent years, in the treatment of cardio vascular disease, peripheral artery disease, post-phlebitis syndrome, complications of diabetes, especially diabetic nephropathy, etc.The clinical application attracted attention, this article on its chemical composition, pharmacokinetics, biological activity,quality control, mechanism and pharmacology, clinical research and applications, and recent research are reviewed.To be compared with similar drugs heparin, sulode xide to special due to be taken orally, the bioavailability of high, fewer side effects, and with heparin no role of the decomposition of fat can be considered more widely applied.Currently only the imported products, domestic manufacturers are in research and development stage, Ibelieve that in the near future will be made to sulodexide in china.

Key words: Sulodexide, Low molecular weight heparin, Dermatan sulfate, Anti-thrombosis, Cardio vascular disease, Diabetic nephropathy

中图分类号:

王亚敏. 舒洛地特研究进展及临床应用[J]. 中国临床药理学与治疗学, 2010, 15(1): 109-115.

WANG Ya-min. Progression of sulodexide and clinical application[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 109-115.

参考文献

[1] Weiss R, Niecestro R, RazI. The role of sulodexide in the treatment of diabetic nephropathy [J]. Drug s, 2007, 67(18):2681-2696.
[2] Abaterusso C, Gambaro G. The role of gly cosamino glycans and sulode xide in the treatment of diabetic nephropathy[J]. Treat Endocrinol, 2006, 5(4):211-222.
[3] Noti C, Seeberger PH. Chemical approaches to define the structure-activity relationship of heparinlike glycosaminogly cans[J]. Chem Bio l, 2005, 12(7):731-756.
[4] Ofosu FA. Pharmacological actions of sulodexide[J]. Semin Thromb Hemost, 1998, 24(2):127-138.
[5] Nenci GG. Dermatan sulphate as an antithrombotic drug[J]. Patho physio l Haemost Thromb, 2002, 32(5/ 6):303-307.
[6] Fabiana AM, Giaquinta RD, Lazzari M. Antithrombotic and anticomplementary propertie s of avery low molecular mass dermatan sulfate [J]. Thromb Res, 2008, 122(1):109-116.
[7] Cristofori M, Mastacchi R, Barbanti M, et al. Pharmacokinetics and distribution of a fluoresceinated glyco samino glycan, sulodexide, in r ats. Par t I: Pharmacokinetics in rats [J]. Arzneimitte lfo rschung, 1985, 35(10):1513-1516.
[8] Harenberg J. Review of pharmacody namics, pharmacokinetics, and therapeutic proper ties of sulodexide[J]. Med Res Rev, 1998, 18(1):1-20.
[9] Ceriello A, Quatraro A, Marchi E. Impaired fibrinoly tic response to increased thrombin activation in type 1 diabetes mellitus: Effects of the glycosaminogly can sulodexide[J]. Diabete Metab, 1993, 19(2):225-229.
[10] Bag lin TP, Carrell RW, Church FC, et al. Cry stal structures of native and thrombincomplexed heparin cofactor II reveal a multistep allosteric mechanism [J]. Proc Natl Acad Sci, 2002, 99(17):11079-11084.
[11] Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diver se proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature [J]. J Bio l Chem, 2001, 276(36):33293-33296.
[12] Tovar AM, de Mattos DA, Stelling MP. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II [J]. Bio chim Biophys Acta, 2005, 1740(1):45-53.
[13] Cosmi B, Cini M, Legnani C. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the antico agula nt effect of sulodex ide, a natural mixture of glycol samino glycans[J]. Thromb Res, 2003, 109(5/6):333-339.
[14] Adiguzel C, Iqbal O, Hoppensteadt D et al. Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide[J]. Clin Appl Thromb Hemost, 2009, 15(5):501-511.
[15] Barbanti M, Guizzardi S, Calanni F, et al. Antithrombotic and thromboly tic activity of sulodexide in rats[J]. Int J Clin Lab Res, 1992, 22(3):179-184.
[16] Iacoviello L, D'Adamo MC, Pawlak K, et al. Antithrombotic activity of derma tan sulphates, heparins and their combination in an animal model of arte rial thrombosis[J]. Thromb Haemost, 1996, 76(6):1102-1107.
[17] Kim SB, Kim SH, Lee MS. Effects of sulodexide on hemostatic factors, lipid profile, and inflammation in chronic peritoneal dialysis patients[J]. Perit Dial Int, 2007, 27(4):456-460.
[18] Ciszewicz M, Polubinska A, Antoniewicz Aet al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity[J]. Tr ansl Res, 2009, 153(3):118-123.
[19] Karo J, Poubinska A, Antoniewicz AA. Anti-inflammatory effect of sulodex ide during acute peritonitis in rats[J]. Blood Purif, 2007, 25(5/6):510-514.
[20] Schafer H, Ma they D, Hugo F. Deposition of the terminal C5b-9 complement complex in infarcted areas of human my ocardium[J]. J Immuno l, 1986, 137(6):1945-1949.
[21] Par k JL, Kilgore KS, Nay lo r KB, et al. Lucchesi BR. N-Acety lheparin pretreatment reduces infarct size in the rabbit[J]. Pharmacology, 1999, 58(3): 120-131.
[22] Tanhehco EJ, Kilgore KS, Naylor KB, et al. Reduction of my ocardial infarct size after ischemia and reperfusion by the gly cosaminogly can pento san poly sulfate[J]. J Cardiovasc Pharmacol, 1999, 34(1):153-161.
[23] Lauver DA, Booth EA, White AJ, et al. Sulodexide attenuates my ocardia l ischemia reperfusion injury and the deposition of C-reactive protein in area s of infarction without affecting hemostasis[J]. J Pharmaco l Ex p The r, 2005, 312(2):794-800.
[24] Friedrichs GS, Kilgore KS, Manley PJet al. Effects of heparin and N-acety l heparin on ischemia reperfusion-induced alterations in myocardial function in the rabbit isolated heart[J]. Cir c Res, 1994, 75(4):701-710.
[25] Black SC, Gralinski M R, Friedrichs GS, et al. Cardio protective effects of heparin or N-ace tylheparin in an in vivo model of myocardial ischaemic and reperfusion injury [J]. Cardiovasc Res, 1995, 29(5):629-636.
[26] Radhakrishnamurthy B, Sharma C, Bhandaru RR, et al. Studies of chemical and biologic proper ties of afraction of sulodexide, a heparin-like gly cosaminog lycan[J]. Athero scle rosis, 1986, 60(2):141-149.
[27] Kristová V, Lí sková S, Sotní ková R, et al. Sulodexide improvese ndothelial dy sfunction in streptozo tocin-induced diabetes in rats[J]. Physio l Res, 2008, 57(3):491-494.
[28] 舒冏, 曾龙驿, 王曼曼, 等. 舒洛地特对大鼠糖尿病肾脏的保护作用及其机制[J]. 中国医院药学杂志,2009, 29(1):19-23.
[29] Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2:a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the fir sty ear after acute myocar dial infarction[J]. J Am Coll Cardiol, 1994, 23(1):27-34.
[30] Errichi BM, Cesarone M R, Belcaro G, et al. Prevention of recur rent deep venous thrombosis with sulodexide: the SanVal registry [J]. Angiology, 2004, 55(3):243-249.
[31] Cirujeda JL, Granado PC. A study on the safety, efficacy, and efficiency of sulodexide compared with ace nocoumarol in secondary prophylaxis in patients with deep venous thrombosis[J]. Angiology, 2006, 57(1):53-64.
[32] Coccheri S, Scondotto G, Agnelli G, et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous legulcers[J]. Thromb Haemost, 2002, 87(6):947-952.
[33] Scondotto G, Aloisi D, Ferrari P, et al. Treatment of venous leg ulcers with sulode xide[J]. Angiolo-gy, 1999, 50(11):883-889.
[34] Coccheri S, Scondotto G, Agnelli G, et al. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicent re, placebo-co ntro lled study[J]. Eur Heart J, 2002, 23(13):1057-1065.
[35] Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in micro albuminuric and macroalbuminuric type 1 and type 2diabe tic patients: the Di. N. A. S. randomized trial[J]. J Am Soc Nephrol, 2002, 13(6):1615-1625.
[36] Heerspink H L, Greene T, Lewis JB, et al. Effects of sulode xide in patients with type 2 diabetes and persistent albuminuria [J]. Nephrol Dial Transplant, 2008, 23(6):1946-1954.
[37] Lambers Heerspink H J, Fowler MJ, Volg i J, et al. Ratio nale for and study design of the sulode xide trials in Type 2 diabetic, hypertensive patients with micro albuminuria or overt nephropathy [J]. Diabet Med, 2007, 24(11):1290-1295.
[38] Burney BO, Kalaitzidis RG, Bakris GL, et al. Novel therapies of diabetic nephropathy [J]. Curr Opin Nephrol Hyper tens, 2009, 18(2):107-111.
[39] Fracasso A, Baggio B, Masiero M, et al. Effect of oral treatment with the gly cosaminog lycan sulodexide on per ito neal transport in CAPD patients[J]. Perit Dial Int, 2003, 23(6):595-599.
[40] Lauver DA, Lucchesi BR. Sulodex ide: a renewed interest in this gly cosaminogly can [J]. Cardiovasc Drug Rev, 2006, 24(3/4):214-226.